Literature DB >> 26188093

Cereblon is recruited to aggresome and shows cytoprotective effect against ubiquitin-proteasome system dysfunction.

Naoya Sawamura1, Satoru Wakabayashi2, Kodai Matsumoto2, Haruka Yamada2, Toru Asahi3.   

Abstract

Cereblon (CRBN) is encoded by a candidate gene for autosomal recessive nonsyndromic intellectual disability (ID). The nonsense mutation, R419X, causes deletion of 24 amino acids at the C-terminus of CRBN, leading to mild ID. Although abnormal CRBN function may be associated with ID disease onset, its cellular mechanism is still unclear. Here, we examine the role of CRBN in aggresome formation and cytoprotection. In the presence of a proteasome inhibitor, exogenous CRBN formed perinuclear inclusions and co-localized with aggresome markers. Endogenous CRBN also formed perinuclear inclusions under the same condition. Treatment with a microtubule destabilizer or an inhibitor of the E3 ubiquitin ligase activity of CRBN blocked formation of CRBN inclusions. Biochemical analysis showed CRBN containing inclusions were high-molecular weight, ubiquitin-positive. CRBN overexpression in cultured cells suppressed cell death induced by proteasome inhibitor. Furthermore, knockdown of endogenous CRBN in cultured cells increased cell death induced by proteasome inhibitor, compared with control cells. Our results show CRBN is recruited to aggresome and has functional roles in cytoprotection against ubiquitin-proteasome system impaired condition.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aggresome; Cereblon; Cytoprotection; Intellectual disability; Ubiquitin-proteasome system

Mesh:

Substances:

Year:  2015        PMID: 26188093     DOI: 10.1016/j.bbrc.2015.07.068

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Ohgata, the Single Drosophila Ortholog of Human Cereblon, Regulates Insulin Signaling-dependent Organismic Growth.

Authors:  Satoru Wakabayashi; Naoya Sawamura; André Voelzmann; Meike Broemer; Toru Asahi; Michael Hoch
Journal:  J Biol Chem       Date:  2016-10-04       Impact factor: 5.157

2.  Cereblon regulates NK cell cytotoxicity and migration via Rac1 activation.

Authors:  Cinzia Fionda; Helena Stabile; Rosa Molfetta; Andrea Kosta; Giovanna Peruzzi; Silvia Ruggeri; Alessandra Zingoni; Cristina Capuano; Alessandra Soriani; Rossella Paolini; Angela Gismondi; Marco Cippitelli; Angela Santoni
Journal:  Eur J Immunol       Date:  2021-09-18       Impact factor: 6.688

3.  Cereblon suppresses the lipopolysaccharide-induced inflammatory response by promoting the ubiquitination and degradation of c-Jun.

Authors:  Jing Yang; Min Huang; Liang Zhou; Xian He; Xiaogang Jiang; Yang Zhang; Guoqiang Xu
Journal:  J Biol Chem       Date:  2018-05-10       Impact factor: 5.157

Review 4.  Cereblon in health and disease.

Authors:  Hyoung Kyu Kim; Tae Hee Ko; Bayalagmaa Nyamaa; Sung Ryul Lee; Nari Kim; Kyung Soo Ko; Byoung Doo Rhee; Chul-Seung Park; Bernd Nilius; Jin Han
Journal:  Pflugers Arch       Date:  2016-06-24       Impact factor: 3.657

5.  Mitochondrial cereblon functions as a Lon-type protease.

Authors:  Kosuke Kataoka; China Nakamura; Toru Asahi; Naoya Sawamura
Journal:  Sci Rep       Date:  2016-07-15       Impact factor: 4.379

6.  Mouse Monoclonal Antibodies Generated from Full Length Human Cereblon: Detection of Cereblon Protein in Patients with Multiple Myeloma.

Authors:  Xiubao Chang; Qinqin Xu; Yuexian Hou; Cynthia Li; Ye Xu; A Keith Stewart
Journal:  Int J Mol Sci       Date:  2017-09-17       Impact factor: 5.923

Review 7.  Cereblon: A Protein Crucial to the Multiple Functions of Immunomodulatory Drugs as well as Cell Metabolism and Disease Generation.

Authors:  Qinglin Shi; Lijuan Chen
Journal:  J Immunol Res       Date:  2017-08-15       Impact factor: 4.818

8.  The Neuroprotective Effect of Thalidomide against Ischemia through the Cereblon-mediated Repression of AMPK Activity.

Authors:  Naoya Sawamura; Mariko Yamada; Miku Fujiwara; Haruka Yamada; Hideki Hayashi; Norio Takagi; Toru Asahi
Journal:  Sci Rep       Date:  2018-02-06       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.